Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

Signalling through the interleukin (IL)-6 pathway induces proliferation and drug resistance of multiple myeloma cells. We therefore sought to determine whether the IL-6-neutralizing monoclonal antibody siltuximab, formerly CNTO 328, could enhance the activity of melphalan, and to examine some of the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Hunsucker, Sally A., Magarotto, Valeria, Kuhn, Deborah J., Kornblau, Steven M., Wang, Michael, Weber, Donna M., Thomas, Sheeba K., Shah, Jatin J., Voorhees, Peter M., Xie, Hong, Cornfeld, Mark, Nemeth, Jeffrey A., Orlowski, Robert Z.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2011
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3402914/
https://ncbi.nlm.nih.gov/pubmed/21241278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2010.08533.x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk